Verastem, Inc. , focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, today announced the initiation of a Phase 1 trial of defactinib , a potent inhibitor of focal adhesion kinase , in Japanese patients with advanced solid tumors.
http://www.businesswire.com/news/topix/20130924005192/en
http://www.businesswire.com/news/topix/20130924005192/en
No comments:
Post a Comment